日本語 
Rhythm Pharmaceuticals and LG Chem have changed their global licensing agreement for bivamelagon, an investigational oral treatment for rare forms of obesity. The new terms increase the value of the agreement from $305 million to $855 million. The royalty system has been. Extra fixed payments have been added for LG Chem.
This change was announced on November 2 2026. It shows that the companies are still focused on creating and selling bivamelagon. Bivamelagon is a small-molecule melanocortin-4 receptor (MC4R) agonist. It is being studied for conditions such as acquired obesity. This is a type of obesity that happens when the hypothalamus is damaged or not working properly.
In the agreement Rhythm will give LG Chem an extra $350 million in fixed payments over four years. The companies have also replaced the royalty system with a fixed 1% royalty on global net sales of products, in Rhythm’s MC4R portfolio. This new structure includes bivamelagon, setmelanotide and RM-718.
Revised Licensing Terms Increase Potential Deal Value
Rhythm originally secured worldwide exclusive rights to develop and commercialize bivamelagon, previously known as LB54640, from LG Chem in January 2024. The original agreement included $80 million in cash payments and $20 million in Rhythm common stock, alongside potential regulatory and commercial milestone payments of up to $205 million.
The amended agreement introduces an additional $350 million in fixed payments, scheduled across four installments:
$70 million within 15 business days following the amendment’s effective date of November 2, 2026.
$100 million in September 2027.
$100 million in September 2028.
$80 million in September 2029.
The revised royalty arrangement will apply from January 1, 2029, or from the first commercial sale of bivamelagon if that occurs earlier. LG Chem will receive a 1% royalty on global net sales across Rhythm’s MC4R portfolio, replacing the previous low-to-mid-single-digit royalty structure, which varied according to the number of approved indications.
The amendment also introduces an additional milestone payment of up to $200 million if Rhythm’s MC4R portfolio reaches $3 billion in annual global net sales. This is in addition to the original potential development, regulatory and commercial milestone payments of up to $205 million.
Consequently, the agreement’s potential value rises to $855 million, excluding the separate ongoing royalty stream. The companies may also agree to convert certain fixed payment obligations into additional royalties.
$750 Million Financing Supports Development and Commercialization
Alongside the licensing amendment, Rhythm announced a five-year term-loan facility providing access to as much as $750 million in capital. The financing is led by KKR’s HealthCare Royalty in partnership with funds managed by Blackstone.
The facility includes $500 million in committed capital. An initial $250 million draw is expected at closing, subject to customary conditions, with up to another $250 million available through June 30, 2028, through three delayed-draw tranches. Rhythm may access an additional $250 million by mutual agreement.
Borrowings will carry interest at the Secured Overnight Financing Rate (SOFR) plus 4.60%. The facility has no scheduled principal amortization before maturity and does not include an equity component.
Rhythm plans to use the financing to support the amended LG Chem agreement, global commercialization activities and continued investment in its research and development pipeline. The company also agreed to amend its existing revenue-interest financing arrangement with HealthCare Royalty, including changes to certain covenants, default provisions and collateral terms.
The financing gives Rhythm additional capital flexibility as it advances its MC4R portfolio. At the same time, the debt structure introduces financing obligations that will need to be managed alongside the costs of clinical development and future commercialization.
Bivamelagon’s Clinical Development Progress
I learned that Bivamelagon is a MC4R agonist designed to target pathways involved in appetite regulation and energy balance. Bivamelagon works by acting on MC4R, which plays a role in the bodys regulation of hunger and body weight. Because MC4R is a player MC4R becomes a target for therapies that address certain rare genetic and acquired obesity conditions.
LG Chem developed Bivamelagon before licensing Bivamelagon to Rhythm in 2024. Rhythm then pushed Bivamelagon forward in development including a Phase 2 study that involved patients with hypothalamic obesity. The companies highlighted that the weight‑loss results were clinically meaningful which supports the idea of expanding the program.
According to reports tied to LG Chems announcement Rhythm is preparing for Phase 3 development and plans to move Bivamelagon into the next stage by the end of 2026. Phase 3 studies will help to establish Bivamelagons safety and efficacy in patient populations. Whether Bivamelagon will receive approval and become commercially available will still depend on the clinical outcomes and on review, by the relevant authorities.
Implications for Japan’s Pharmaceutical and Biotech Sector
The updated agreement is important for the pharmaceutical industry because it shows how licensing partnerships help biotechnology companies move drug candidates across different markets.
Japanese pharmaceutical companies and biotech firms are working more and more in a development setting where research skills clinical trial networks and commercialization tools can be spread across many places. Licensing agreements let the original developer earn from its research and give a partner the job of later-stage development and market access.
The Rhythm-LG Chem agreement also shows how licensing economics grow as a drug candidate moves through development. Additional fixed payments give LG Chem an idea of contract money while the simplified royalty plan gives Rhythm a steady rate, across its MC4R portfolio. The possible $200 million sales milestone ties part of the agreements value to the portfolios sales.
For drug developers the deal shows how important it is to negotiate licensing structures that balance money, development milestones, royalties and long-term commercial potential. It also shows how specialist healthcare investors help finance companies that need commercialization resources.
A Strategic Step Toward Global Development
Also Read: Zeal Launches MEDSCOPE for OTC Pharma Data Analysis
The amendment makes the commercial setup that supports bivamelagons growth stronger. LG Chem gets fixed payments and a simpler way to pay royalties while Rhythm gets better licensing terms and funding to help with its bigger plan for other medicines and getting them to market.
The deal does not promise that the regulators will say yes or that the medicine will be successful. Bivamelagon is still being. What happens next depends on more studies and what the regulators decide.
Still the bigger deal shows how partnerships in the pharmaceutical industry can change as medicines move through the process of being developed. For the biotechnology industry it is a sign of how companies that create medicines and those that help sell them around the world can change the way money is handled to help with the next step of research and possible growth, in the market.
English